<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347577">
  <stage>Registered</stage>
  <submitdate>10/10/2011</submitdate>
  <approvaldate>28/10/2011</approvaldate>
  <actrnumber>ACTRN12611001130954</actrnumber>
  <trial_identification>
    <studytitle>The Effects of Narrow Band Ultraviolet B (UVB) Phototherapy on Vitamin D levels in patients with Psoriasis and Broad band Ultraviolet B and A used for dermatitis</studytitle>
    <scientifictitle>Patients with Psoriais and Dermatitis The Effects of Ultraviolet B and A Phototherapy On Vitamin D levels</scientifictitle>
    <utrn>U1111-1125-1431</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D levels</healthcondition>
    <healthcondition>Psoriasis</healthcondition>
    <healthcondition>Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with psoriasis and severe dermatitis will attend 3 times weekly for a minimal of 6 and in many case 10 or more weeks. Each treatment is on average 5 minutes. There are no phototherapy cabinets in the hospital public system. Patients will enter phototherapy cabinets located at the Fremantle Dermatology Clinic. They all start on a low dose according to their skin type and are pushed up in dosage depending on their response to treatment. All that is different is we will be drawing pre and in treatment blood to measure Vitamin D levels.

The minimum dose for Phototherapy is 0.05 joules and the maximum dose is 1.20 joules for Narrowband UVB and UVA. 

Pre-treatment and post treatment bloods will be 5ml each time. For Vitamin D Assay an amount of 1/2 - 1 SST tube needs to be taken (ie max 5mls).

All patients will have at least a minimal of 4-6 weeks of treatment at three times a week.  This would be a minimum requirement to a Phototherapy patient to achieve some therapeutic response.  In regards to those that achieve a very good response, we will be titrating their treatment.  Those that require a longer response will continue on.  It is suggested that we chase the Vitamin D at the 6 week margin automatically so that all patients will have standardised 3 times week treatment course for 6 weeks.</interventions>
    <comparator>NA</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>We propose to measure Vitamin D levels in patients pre and post UVB phototherapy through a blood test measuring serum levels of Vitamin D.</outcome>
      <timepoint>Vitamin D levels will be measured at the start of treatment (baseline, time 0) and then again at the completion of treatment (varying from 2 to 6 months).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>NA</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with dermatological skin conditions (psoriasis, severe dermatitis) undergoing UVB or UVA phototherapy, not currently taking Vitamin D or calcium supplements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients on Vitamin D / calcium supplements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/11/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Kurt Gebauer</primarysponsorname>
    <primarysponsoraddress>High Street
Fremantle WA 6160</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Fremantle Dermatology</fundingname>
      <fundingaddress>High Street
Fremantle WA 6160</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We propose to measure Vitamin D levels in a group of patients attending the Fremantle Dermatology clinic pre and post UVB and UVA phothterapy, to see whether there is any change in the levels post phototherapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Fremantle Hospital Ethics Committee</ethicname>
      <ethicaddress>Alma Street
Fremantle WA 6160</ethicaddress>
      <ethicapprovaldate />
      <hrec>NA</hrec>
      <ethicsubmitdate>30/10/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jenny Tu</name>
      <address>Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+610893463333</phone>
      <fax />
      <email>jenny.tu@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jenny Tu</name>
      <address>Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+610893463333</phone>
      <fax />
      <email>jenny.tu@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jenny Tu</name>
      <address>Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+610893463333</phone>
      <fax />
      <email>jenny.tu@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>